CareDx (NASDAQ:CDNA) Announces Earnings Results

by · The Cerbat Gem

CareDx (NASDAQ:CDNA – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.14, FiscalAI reports. The company had revenue of $131.95 million during the quarter, compared to analyst estimates of $113.83 million. CareDx had a net margin of 24.23% and a return on equity of 3.14%. The business’s revenue for the quarter was up 52.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.16) EPS.

Here are the key takeaways from CareDx’s conference call:

  • Q2 revenue rose 52% to $132 million, while testing services revenue increased 61% to $100 million and adjusted EBITDA reached $25 million, or 19% of revenue. The company also ended the quarter with $374 million in cash and no debt.
  • CareDx raised its 2026 guidance to $490 million–$500 million in revenue and $66 million–$78 million in adjusted EBITDA, including $24 million of second-half specialty oncology revenue and 258,000–266,000 tests for the year.
  • Transplant testing growth remains strong, with Q2 volume up 17% to 58,000 tests as both surveillance and for-cause use expanded. Management cited broader clinical adoption, improved workflows, and evidence supporting AlloSure’s use in risk assessment and treatment monitoring.
  • The company reported progress across its growth pipeline and NavDx acquisition, including a planned 2027 AlloHeme commercial launch, a 2026 clinical-study launch for HistoMap Kidney, and integration initiatives intended to expand NavDx adoption and improve reimbursement and workflow efficiency.
  • Management characterized its outlook as prudent while it integrates NavDx billing and operating systems; specialty oncology is currently modeled at roughly 63% gross margin and may require additional investment, although CareDx continues to target approximately 20% long-term adjusted EBITDA margins.

CareDx Trading Up 14.7%

NASDAQ:CDNA opened at $43.71 on Friday. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of 21.12 and a beta of 2.43. CareDx has a 1-year low of $11.26 and a 1-year high of $45.00. The business’s fifty day moving average price is $28.59 and its 200 day moving average price is $22.61.

Wall Street Analyst Weigh In

Several analysts recently commented on CDNA shares. BTIG Research increased their target price on shares of CareDx from $28.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. Craig Hallum reiterated a “hold” rating and set a $35.00 price objective on shares of CareDx in a research report on Thursday, July 16th. HC Wainwright reissued a “neutral” rating and set a $46.00 price objective on shares of CareDx in a research note on Friday. Finally, Weiss Ratings upgraded CareDx from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $36.75.

Get Our Latest Report on CDNA

Insider Transactions at CareDx

In related news, Director Hannah Valantine sold 12,103 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the sale, the director directly owned 36,686 shares in the company, valued at approximately $847,813.46. This trade represents a 24.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Walter Hanna, Jr. sold 39,900 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $29.24, for a total transaction of $1,166,676.00. Following the sale, the chief executive officer owned 661,959 shares of the company’s stock, valued at approximately $19,355,681.16. This represents a 5.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 78,936 shares of company stock valued at $2,093,708 over the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of CareDx by 1.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company’s stock valued at $739,000 after buying an additional 711 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company’s stock valued at $542,000 after acquiring an additional 1,280 shares in the last quarter. Quarry LP acquired a new position in shares of CareDx in the fourth quarter worth $25,000. Franklin Resources Inc. increased its stake in shares of CareDx by 3.8% in the fourth quarter. Franklin Resources Inc. now owns 103,703 shares of the company’s stock worth $1,954,000 after acquiring an additional 3,774 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of CareDx by 120.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,608 shares of the company’s stock worth $149,000 after acquiring an additional 4,160 shares in the last quarter.

Key Headlines Impacting CareDx

Here are the key news stories impacting CareDx this week:

  • Positive Sentiment: CareDx reported second-quarter adjusted earnings of $0.37 per share, exceeding the $0.22 analyst consensus and improving from $0.10 in the year-ago quarter. CareDx Beats Q2 Earnings and Revenue Estimates
  • Positive Sentiment: Revenue rose 52.2% year over year to $131.95 million, well above the $113.83 million consensus estimate. The sizable revenue beat signals continued demand growth and operating momentum. CareDx Q2 Non-GAAP Earnings and Revenue Outlook
  • Positive Sentiment: The company raised its 2026 revenue outlook to $490 million-$500 million, substantially above the roughly $455.7 million analyst expectation. The guidance increase is likely the most important catalyst for the stock because it points to stronger full-year growth than previously anticipated. CareDx Announces Second Quarter 2026 Financial Results
  • Neutral Sentiment: Management’s earnings call and presentation provided additional detail on the quarter and updated outlook, reinforcing the market’s focus on revenue growth and execution through the remainder of 2026. CareDx Q2 2026 Earnings Call Transcript
  • Negative Sentiment: Despite the adjusted earnings beat, CareDx continued to report a negative net margin, suggesting profitability remains a risk while the company scales its business. CareDx Q2 Earnings Snapshot

CareDx Company Profile

(Get Free Report)

CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.

The company’s core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.

See Also